Citations

Mayo Clinic

Showing 10 of 108572 citations.

Investigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis
Taylor, Amy E. , Martin, Richard M. , Geybels, Milan S., Stanford, Janet L. , Shui, Irene M. , Eeles, Rosalind A. , Easton, Doug , Olama, Ali Amin Al , Benlloch, Sara, Muir, Kenneth , Grönberg, Henrik , Haiman, Christopher A. , Schleutker, Johanna , Nordestgaard, Børge G. , Travis, Ruth C. , Neal, David E. , Pashayan, Nora , Blot, William J. , Thibodeau, Stephen N. , Maier, Christiane, Kibel, Adam S. , Brenner, Hermann , Park, Jong, Kaneva, Radka , Batra, Jyotsna , Teixeira, Manuel R. , Pandha, Hardev, Donovan, Jenny , Munafò, Marcus R. , Thibodeau, Stephen, Easton, Douglas F. , Kote‐Jarai, Zsofia , Giles, Graham G. , Wiklund, Fredrik E. , Khaw, Kay‐Tee , Cybulski, Cezary , Cannon‐Albright, Lisa , Teixeira, Manuel R , Eeles, Rosalind A , Donovan, Jenny L , Muir, Kenneth , Schleutker, Johanna , Travis, Ruth C , Pashayan, Nora , Brenner, Hermann , Martin, Richard M , Batra, Jyotsna

International Journal of Cancer | October 14, 2016 | Volume: 140 | Issue: 2 | Pages: 322-328

10.1002/ijc.30462 | PMID 27741566 Get It

Coffee consumption has been shown in some studies to be associated with lower risk of prostate cancer. However, it is unclear if this association is causal or due to confounding or reverse causality. We conducted a Mendelian randomisation analysis to investigate the causal effects of coffee consumption on prostate cancer risk and progression. We used two genetic variants robustly associated with caffeine intake (rs4410790 and rs2472297) as proxies for coffee consumption in a sample of 46,687 men of European ancestry from 25 studies in the PRACTICAL consortium. Associations between genetic variants and prostate cancer case status, stage and grade were assessed by logistic regression and with all‐cause and prostate cancer‐specific mortality using Cox proportional hazards regression. There was no clear evidence that a genetic risk score combining rs4410790 and rs2472297 was associated with prostate cancer risk (OR per additional coffee increasing allele: 1.01, 95% CI: 0.98,1.03) or having high‐grade compared to low‐grade disease (OR: 1.01, 95% CI: 0.97,1.04). There was some evidence that the genetic risk score was associated with higher odds of having nonlocalised compared to localised stage disease (OR: 1.03, 95% CI: 1.01, 1.06). Amongst men with prostate cancer, there was no clear association between the genetic risk score and all‐cause mortality (HR: 1.00, 95% CI: 0.97,1.04) or prostate cancer‐specific mortality (HR: 1.03, 95% CI: 0.98,1.08). These results, which should have less bias from confounding than observational estimates, are not consistent with a substantial effect of coffee consumption on reducing prostate cancer incidence or progression.
Next-generation multiple myeloma treatment: a pharmacoeconomic perspective
Rajkumar, S. Vincent , Harousseau, Jean Luc, Rajkumar, S Vincent

Blood | October 14, 2016 | Volume: 128 | Issue: 24 | Pages: 2757-2764

10.1182/blood-2016-09-692947 | PMID 27742709 Get It

Abstract Advances in the diagnosis and treatment of multiple myeloma have come at a rapid pace, especially with several new drugs entering the market in the last few years. However, access to and affordability of new treatments poses a major challenge, both in the United States and around the world. High costs of life-saving drugs are detrimental to both the personal finances of the individual patient, as well as society which must bear the increasing costs in terms of increased health insurance premiums, taxes, or both. The challenges are not unique to myeloma, but are commonly encountered in several other cancers as well. But to some extent these pharmacoeconomic concerns are amplified in myeloma due to the need for multidrug regimens that combine 2 or more expensive new drugs, continuous therapy, and the prolonged disease course in most patients. We examine current myeloma therapy from a pharmacoeconomic perspective, and discuss the costs involved. We outline the underlying reasons why cancer drugs are so expensive, the measures that are required to lower cost, and propose potential ways in which costs can be reduced while still delivering high-quality care.
Kidney function and appropriateness of device therapies in adults with implantable cardioverter defibrillators
Szpiro, Adam A. , Masoudi, Frederick A. , Greenlee, Robert T. , Smith, David H. , Magid, David J. , Gurwitz, Jerry H. , Tabada, Grace H., Sung, Sue Hee, Dighe, Ashveena , Garcia‐Montilla, Romel , Hammill, Stephen C., Hayes, John, Kadish, Alan H. , Sharma, Param , Varosy, Paul D. , Vidaillet, Humberto, Go, Alan S. , Hammill, Stephen, Bansal, Nisha , Reynolds, Kristi , Cassidy‐Bushrow, Andrea E.

Heart | October 14, 2016 | Volume: 103 | Issue: 7 | Pages: 529-537

10.1136/heartjnl-2016-309842 | PMID 27742796 Get It

Objective Patients with chronic kidney disease (CKD) have higher risk of sudden cardiac death; however, they may not receive implantable cardioverter defibrillators (ICDs), in part due to higher risk of complications. We evaluated whether CKD is associated with greater risk of device-delivered shocks/antitachycardia pacing (ATP) therapies among patients receiving a primary prevention ICD. Methods We studied participants in the observational Cardiovascular Research Network Longitudinal Study of Implantable Cardioverter Defibrillators. CKD was defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2. Outcomes included all delivered shocks/ATPs therapies and type of shock/ATP therapies (inappropriate or appropriate, determined by physician adjudication) within the 3 years. We evaluated the associations between CKD and time to first device therapy, burden of device therapy, and inappropriate versus appropriate device therapy, adjusting for demographics, comorbidity, laboratory values and medication use. Results Among 2161 participants, 1066 (49.3%) had CKD (eGFR 44±11 mL/min/1.73 m2) at ICD implantation. During mean of 2.26±0.89 years, 9.8% and 18.5% of participants had at least one inappropriate and appropriate shock/ATP therapies, respectively. CKD was not associated with time to first shock/ATP therapies (adjusted HR 0.87, 95% CI 0.73 to 1.05), overall burden of shock/ATP therapies (adjusted relative rate 0.93, 95% CI 0.74 to 1.17) or inappropriate versus appropriate shock/ATP therapies (adjusted relative risk 0.88, 95% CI 0.68 to 1.14) compared with not having CKD. Conclusions In adults receiving a primary prevention ICD, mild-to-moderate CKD was not associated with the timing, burden or appropriateness of subsequent device therapy. Potential concern for inappropriate ICD-delivered therapies should not preclude ICDs among eligible patients with CKD.
Pyrolytic Carbon Arthroplasty versus Suspensionplasty for Trapezial-Metacarpal Arthritis
Rizzo, Marco , Moran, Steven L. , Vitale, Mark A. , Hsu, Chao‐Yu

Journal of Wrist Surgery | October 14, 2016 | Volume: 06 | Issue: 02 | Pages: 134-143

10.1055/s-0036-1593735 | PMID 28428915 Get It

Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma
Chang, Anne Lynn S. , Lewis, Karl D. , Arron, Sarah T. , Migden, Michael R. , Yoo, Simon , Day, Bann‐Mo, McKenna, Edward , Sekulić, Aleksandar , Solomon, James A.

Oncotarget | October 14, 2016 | Volume: 7 | Issue: 46 | Pages: 76118-76124

10.18632/oncotarget.12660 | PMID 27764798 Get It

Multi‐institutional experience of stereotactic body radiotherapy for large (≥5 centimeters) non–small cell lung tumors
Shostrom, Valerie , Kumar, Sameera , Zhen, Weining, Hallemeier, Christopher L. , Holland, John , Harkenrider, Matthew M. , Iskhanian, Adrian S., Neboori, Hanmanth J., Attia, Albert, Lee, Percy , Alite, Fiori , Walker, Joshua M. , Stahl, John M. , Wang, Kyle , Bingham, Brian , Hadzitheodorou, C., Decker, Roy H. , McGarry, Ronald C., Simone, Charles B. , Verma, Vivek , Hallemeier, Christopher Leigh , Braunstein, Steve , Jabbour, Salma K , Simone, Charles B

Cancer | October 14, 2016 | Volume: 123 | Issue: 4 | Pages: 688-696

10.1002/cncr.30375 | PMID 27741355 Get It

BACKGROUNDStereotactic body radiotherapy (SBRT) is the standard of care for patients with nonoperative, early‐stage non–small cell lung cancer (NSCLC) measuring < 5 cm, but its use among patients with tumors measuring ≥5 cm is considerably less defined, with the existing literature limited to small, single‐institution reports. The current multi‐institutional study reported outcomes evaluating the largest such population reported to date.METHODSClinical/treatment characteristics, outcomes, toxicities, and patterns of failure were assessed in patients with primary NSCLC measuring ≥5 cm without evidence of distant/lymph node metastasis who underwent SBRT using ≤5 fractions. Statistics included Kaplan‐Meier survival analyses and univariate/multivariate Cox proportional hazards models.RESULTSA total of 92 patients treated from 2004 through 2016 were analyzed from 12 institutions. The median follow‐up was 12 months (15 months in survivors). The median age and tumor size among the patients were 73 years (range, 50‐95 years) and 5.4 cm (range, 5.0‐7.5 cm), respectively. The median dose/fractionation was 50 Gray/5 fractions. The actuarial local control rates at 1 year and 2 years were 95.7% and 73.2%, respectively. The disease‐free survival rate was 72.1% and 53.5%, respectively, at 1 year and 2 years. The 1‐year and 2‐year disease‐specific survival rates were 95.5% and 78.6%, respectively. The median, 1‐year, and 2‐year overall survival rates were 21.4 months, 76.2%, and 46.4%, respectively. On multivariate analysis, lung cancer history and pre‐SBRT positron emission tomography maximum standardized uptake value were found to be associated with overall survival. Posttreatment failures were most commonly distant (33% of all disease recurrences), followed by local (26%) and those occurring elsewhere in the lung (23%). Three patients had isolated local failures. Grade 3 to 4 toxicities included 1 case (1%) and 4 cases (4%) of grade 3 dermatitis and radiation pneumonitis, respectively (toxicities were graded according to the Common Terminology Criteria for Adverse Events [version 4.0]). Grades 2 to 5 radiation pneumonitis occurred in 11% of patients. One patient with a tumor measuring 7.5 cm and a smoking history of 150 pack‐years died of radiation pneumonitis.CONCLUSIONSThe results of the current study, which is the largest study of patients with NSCLC measuring ≥5 cm reported to date, indicate that SBRT is a safe and efficacious option. Cancer 2017;123:688–696. © 2016 American Cancer Society.
Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia
Barraco, Daniela , Finke, Christy M. , Ketterling, Rhett P. , Gangat, Naseema , Hanson, Curtis A. , Tefferi, Ayalew , Patnaik, Mrinal M. , Zahid, Mohammad Faizan, Lasho, Terra L. , Zahid, Mohammad Faizan , Ketterling, Rhett P

Leukemia & Lymphoma | October 14, 2016 | Volume: 58 | Issue: 6 | Pages: 1488-1493

10.1080/10428194.2016.1243681 | PMID 27739921 Get It

Pipeline for uncoilable or failed aneurysms: 3-year follow-up results
Becske, Tibor , Potts, Matthew B. , Shapiro, Maksim , Kallmes, David F. , Brinjikji, Waleed , Saatçi, Işıl , McDougall, Cameron G. , Szikora, István , Moran, Christopher J. , Woo, Henry H. , Berez, Aaron L., Cher, Daniel , Siddiqui, Adnan H. , Albuquerque, Felipe C. , Berentei, Zsolt, Marosföi, Miklós , Cekirge, Saruhan H., Nelson, Peter K. , Lanzino, Giuseppe , Lopes, Demetrius K. , Levy, Elad I. , Fiorella, David , Siddiqui, Adnan H , Szikora, Istvan

Journal of Neurosurgery | October 14, 2016 | Volume: 127 | Issue: 1 | Pages: 81-88

10.3171/2015.6.jns15311 | PMID 27739944 Get It

OBJECTIVEThe long-term effectiveness of endovascular treatment of large and giant wide-neck aneurysms using traditional endovascular techniques has been disappointing, with high recanalization and re-treatment rates. Flow diversion with the Pipeline Embolization Device (PED) has been recently used as a stand-alone therapy for complex aneurysms, showing significant improvement in effectiveness while demonstrating a similar safety profile to stent-supported coil treatment. However, relatively little is known about its long-term safety and effectiveness. Here the authors report on the 3-year safety and effectiveness of flow diversion with the PED in a prospective cohort of patients with large and giant internal carotid artery aneurysms enrolled in the Pipeline for Uncoilable or Failed Aneurysms (PUFS) trial.METHODSThe PUFS trial is a prospective study of 107 patients with 109 aneurysms treated with the PED. Primary effectiveness and safety end points were demonstrated based on independently monitored 180-day clinical and angiographic data. Patients were enrolled in a long-term follow-up protocol including 1-, 3-, and 5-year clinical and imaging follow-up. In this paper, the authors report the midstudy (3-year) effectiveness and safety data.RESULTSAt 3 years posttreatment, 74 subjects with 76 aneurysms underwent catheter angiography as required per protocol. Overall, complete angiographic aneurysm occlusion was observed in 71 of these 76 aneurysms (93.4% cure rate). Five aneurysms were re-treated, using either coils or additional PEDs, for failure to occlude, and 3 of these 5 were cured by the 3-year follow-up. Angiographic cure with one or two treatments of Pipeline embolization alone was therefore achieved in 92.1%. No recanalization of a previously completely occluded aneurysm was noted on the 3-year angiograms. There were 3 (2.6%) delayed device- or aneurysm-related serious adverse events, none of which led to permanent neurological sequelae. No major or minor late-onset hemorrhagic or ischemic cerebrovascular events or neurological deaths were observed in the 6-month through 3-year posttreatment period. Among 103 surviving patients, 85 underwent functional outcome assessment in which modified Rankin Scale scores of 0–1 were demonstrated in 80 subjects.CONCLUSIONSPipeline embolization is safe and effective in the treatment of complex large and giant aneurysms of the intracranial internal carotid artery. Unlike more traditional endovascular treatments, flow diversion results in progressive vascular remodeling that leads to complete aneurysm obliteration over longer-term follow-up without delayed aneurysm recanalization and/or growth.Clinical trial registration no.: NCT00777088 (clinicaltrials.gov)
Incidence and risk factors of posttraumatic seizures following traumatic brain injury: A Traumatic Brain Injury Model Systems Study
Ritter, Anne C., Wagner, Amy K. , Fabio, Anthony , Pugh, Mary Jo , Szaflarski, Jerzy P. , Zafonte, Ross , Brown, Allen W. , Bushnik, Tamara , Johnson‐Greene, Douglas, Shea, Timothy, Krellman, Jason W. , Rosenthal, Joseph , Dreer, Laura E. , Walker, William C. , Hammond, Flora M. , Johnson‐Greene, Doug , Dreer, Laura E

Epilepsia | October 14, 2016 | Volume: 57 | Issue: 12 | Pages: 1968-1977

10.1111/epi.13582 | PMID 27739577 Get It

SummaryObjectiveDetermine incidence of posttraumatic seizure (PTS) following traumatic brain injury (TBI) among individuals with moderate‐to‐severe TBI requiring rehabilitation and surviving at least 5 years.MethodsUsing the prospective TBI Model Systems National Database, we calculated PTS incidence during acute hospitalization, and at years 1, 2, and 5 postinjury in a continuously followed cohort enrolled from 1989 to 2000 (n = 795). Incidence rates were stratified by risk factors, and adjusted relative risk (RR) was calculated. Late PTS associations with immediate (<24 h), early (24 h–7 day), or late seizures (>7 day) versus no seizure prior to discharge from acute hospitalization was also examined.ResultsPTS incidence during acute hospitalization was highest immediately (<24 h) post‐TBI (8.9%). New onset PTS incidence was greatest between discharge from inpatient rehabilitation and year 1 (9.2%). Late PTS cumulative incidence from injury to year 1 was 11.9%, and reached 20.5% by year 5. Immediate/early PTS RR (2.04) was increased for those undergoing surgical evacuation procedures. Late PTS RR was significantly greater for individuals who self‐identified as a race other than black/white (year 1 RR = 2.22), and for black individuals (year 5 RR = 3.02) versus white individuals. Late PTS was greater for individuals with subarachnoid hemorrhage (year 1 RR = 2.06) and individuals age 23–32 (year 5 RR = 2.43) and 33–44 (year 5 RR = 3.02). Late PTS RR years 1 and 5 was significantly higher for those undergoing surgical evacuation procedures (RR: 3.05 and 2.72, respectively).SignificanceIn this prospective, longitudinal, observational study, PTS incidence was similar to that in studies published previously. Individuals with immediate/late seizures during acute hospitalization have increased late PTS risk. Race, intracranial pathologies, and neurosurgical procedures also influenced PTS RR. Further studies are needed to examine the impact of seizure prophylaxis in high‐risk subgroups and to delineate contributors to race/age associations on long‐term seizure outcomes.
Varying Degrees of Temporoparietal Hypometabolism on FDG-PET Reveal Amyloid-Positive Logopenic Primary Progressive Aphasia is not a Homogeneous Clinical Entity
Krishnan, K. Ranga, Whitwell, Jennifer L. , Butts, Alissa M. , Senjem, Matthew L. , Spychalla, Anthony J., Jack, Clifford R. , Lowe, Val J. , Josephs, Keith A. , Krishnan, Kamini, Strand, Edythe A. , Machulda, Mary M. , Duffy, Joseph R. , Jack, Clifford R , Senjem, Matthew L

Journal of Alzheimer's Disease | October 14, 2016 | Volume: 55 | Issue: 3 | Pages: 1019-1029

10.3233/jad-160614 | PMID 27802232 Get It